Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,706 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all

Conditions: AIDS
Interventions: GSK Biologicals HIV Vaccine 732462, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 17
States / cities: Bakersfield, California • Long Beach, California • Washington D.C., District of Columbia + 13 more

Conditions: HIV Infection
Interventions: N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Human Immunodeficiency Virus
Interventions: Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes; Drug · Biological
Lead sponsor: Calimmune, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: HIV Infections
Interventions: Alovudine; Drug
Lead sponsor: Lederle Laboratories; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV, HIV Infections
Interventions: Energex HemoModulator; Device
Lead sponsor: Energex Systems, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: HIV-1
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-1 Infection
Interventions: darunavir, ritonavir, zidovudine, lamivudine, abacavir; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: HIV-1-infection, Gut Inflammation
Interventions: Pentasa vs Align; Drug
Lead sponsor: AIDS Healthcare Foundation; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Community-Level Intervention; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 15 Years to 25 Years · Male only
Enrollment: 12,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2004
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 5 more

Conditions: HIV Disease
Interventions: α1 Proteinase Inhibitor, Placebos; Biological · Drug
Lead sponsor: Institute for Human Genetics and Biochemistry; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 5
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more

Conditions: HIV Infections
Interventions: chloroquine phosphate, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232, Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infection Primary
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: HIV Infections
Interventions: Dextran sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Ad26.Mos4.HIV, Clade C and Mosaic gp140 HIV bivalent vaccine, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 3,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more

Conditions: Hemophilia, AIDS
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 100 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2020
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Indianapolis, Indiana + 11 more

Conditions: HIV Infection, Healthy
Interventions: Silymarin (milk thistle); Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Human Immunodeficiency Virus, HIV/AIDS
Interventions: Social Network Training, Single Care-Related Counseling Session and Referral to Care; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV Infections
Interventions: Couples HIV testing and counseling, Individual HIV testing and counseling; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 17 Years to 65 Years · Male only
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • New York, New York

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 15
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Human Immunodeficiency Virus
Interventions: TMB-607, Placebo; Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 75
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more

Search by objective public record fields.

Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects

Safety Study of the HemoModulator System for the Treatment of Patients With Human Immunodeficiency Virus (HIV)

Interventions to Decrease the Risk of Mother-to-Child Transmission of HIV in India

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

Community Intervention Trial for Youth (CITY) Study

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

Assessing Differential Adherence to Medications and Quality of Life Among People Living With HIV and Comorbidities

Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)

The Effect of Milk Thistle on the Pharmacokinetics of Indinavir

Social Network Intervention to Engage Community PLH to Engage in HIV Medical Care

Evaluating the Efficacy of Annual CHTC Retesting Among Male Couples at High Risk of HIV Infection

Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)